Skip to main content
NVDA-2.37%AAPL+1.52%GOOGL-0.14%MSFT+0.05%AMZN+0.02%TSM-1.10%SPCX+3.00%AVGO-0.14%META-0.14%TSLA-0.38%SKHY-3.41%MU-4.64%BRK-B-0.21%LLY+0.23%JPM-0.66%AMD-3.07%WMT+0.18%V+0.04%XOM+0.55%ASMLa-1.66%JNJ-0.39%INTC-4.87%MA-0.29%0700.HK-1.94%ORCL-2.91%1398.HK+0.79%BAC-0.63%ABBV+0.44%CSCO-0.88%CVX-0.04%COST+0.20%LRCX-4.56%KO+1.10%CAT-1.54%AMAT-2.25%0005.HK-0.78%AP2d-1.55%UNH-0.45%DELL-3.44%HSBA.L-1.30%MS-0.79%PG-0.14%GE-0.25%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.18%HD-1.17%GS-0.92%0939.HK+1.66%NZDJPY-2.58%AUDJPY-1.83%CHFJPY-1.56%NZDCAD-1.46%EURNZD+1.41%GBPNZD+1.36%USDJPY-1.32%NZDUSD-1.29%GBPJPY-1.23%EURJPY-1.21%CADJPY-1.14%NZDCHF-1.05%USDZAR+0.91%EURZAR+0.85%AUDNZD+0.77%GBPZAR+0.77%USDNOK+0.76%USDSEK+0.75%AUDCAD-0.73%EURNOK+0.69%EURSEK+0.68%AUDDKK-0.66%EURAUD+0.63%GBPAUD+0.59%CHFNOK+0.56%CHFSEK+0.55%AUDUSD-0.52%AUDSGD-0.52%USDTHB+0.48%USDMXN+0.44%GBPTRY+0.41%CADCHF+0.41%NZDSGD-0.36%EURCHF+0.34%NOKJPY-0.33%GBPHKD+0.32%GBPCHF+0.32%USDPLN+0.31%GBPMXN-0.28%AUDCHF-0.28%USDCHF+0.25%EURPLN+0.24%SGDJPY+0.22%USDSGD+0.21%USDCAD-0.17%USDILS+0.16%NZDMXN-0.15%EURSGD+0.14%PLNJPY+0.11%GBPCAD-0.11%USDTRY+0.11%EURUSD+0.10%GBPUSD+0.08%EURCZK-0.08%EURHKD-0.08%USDCNH+0.08%EURCAD-0.08%USDDKK+0.06%GBPSGD+0.05%USDCOP-0.04%EURGBP+0.04%EURCNH+0.03%AUDNOK+0.03%USDHKD+0.01%CHFSGD+0.01%EURDKK0.00%XPTUSD-5.33%UKOIL+5.05%USOIL+4.73%HG1-4.70%XAGUSD-4.69%GAGUSD-4.68%SUGAR+2.54%GAUUSD-0.96%XAUUSD-0.96%COTTON+0.72%COFFEE-0.69%XNGUSD+0.64%BTCUSD-1.69%ETHUSD-1.24%USDTUSD-0.03%XRPUSD-3.15%SOLUSD-2.10%TRXUSDT0.00%ZECUSDT-7.17%DOGEUSD-3.23%XMRUSDT-1.42%LINKUSD-1.94%XLMUSD-2.45%BCHUSDT-10.50%LTCUSD-2.25%UNIUSD-2.93%TONUSD+24.88%HBARUSDT-2.55%SUIUSD-4.12%TAOUSDT-6.03%AAVEUSD-3.38%DOTUSDT-3.52%ICPUSDT-1.55%ONDOUSDT-3.87%WLDUSDT-3.39%ARBUSDT-0.70%ATOMUSDT-5.46%JUPUSDT-4.25%INJUSDT-5.73%STXUSDT-4.53%FETUSDT-4.21%TIAUSDT-2.18%PYTHUSDT-1.56%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-2.97%WIFUSDT-5.87%OPUSDT-4.00%POLUSDT-6.02%IOTAUSDT-4.48%AXSUSDT-2.90%FARTCOINUSDT-4.36%EOSUSDT-1.67%DYDXUSDT-3.33%ORDIUSDT-1.82%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.37%AAPL+1.52%GOOGL-0.14%MSFT+0.05%AMZN+0.02%TSM-1.10%SPCX+3.00%AVGO-0.14%META-0.14%TSLA-0.38%SKHY-3.41%MU-4.64%BRK-B-0.21%LLY+0.23%JPM-0.66%AMD-3.07%WMT+0.18%V+0.04%XOM+0.55%ASMLa-1.66%JNJ-0.39%INTC-4.87%MA-0.29%0700.HK-1.94%ORCL-2.91%1398.HK+0.79%BAC-0.63%ABBV+0.44%CSCO-0.88%CVX-0.04%COST+0.20%LRCX-4.56%KO+1.10%CAT-1.54%AMAT-2.25%0005.HK-0.78%AP2d-1.55%UNH-0.45%DELL-3.44%HSBA.L-1.30%MS-0.79%PG-0.14%GE-0.25%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.18%HD-1.17%GS-0.92%0939.HK+1.66%NZDJPY-2.58%AUDJPY-1.83%CHFJPY-1.56%NZDCAD-1.46%EURNZD+1.41%GBPNZD+1.36%USDJPY-1.32%NZDUSD-1.29%GBPJPY-1.23%EURJPY-1.21%CADJPY-1.14%NZDCHF-1.05%USDZAR+0.91%EURZAR+0.85%AUDNZD+0.77%GBPZAR+0.77%USDNOK+0.76%USDSEK+0.75%AUDCAD-0.73%EURNOK+0.69%EURSEK+0.68%AUDDKK-0.66%EURAUD+0.63%GBPAUD+0.59%CHFNOK+0.56%CHFSEK+0.55%AUDUSD-0.52%AUDSGD-0.52%USDTHB+0.48%USDMXN+0.44%GBPTRY+0.41%CADCHF+0.41%NZDSGD-0.36%EURCHF+0.34%NOKJPY-0.33%GBPHKD+0.32%GBPCHF+0.32%USDPLN+0.31%GBPMXN-0.28%AUDCHF-0.28%USDCHF+0.25%EURPLN+0.24%SGDJPY+0.22%USDSGD+0.21%USDCAD-0.17%USDILS+0.16%NZDMXN-0.15%EURSGD+0.14%PLNJPY+0.11%GBPCAD-0.11%USDTRY+0.11%EURUSD+0.10%GBPUSD+0.08%EURCZK-0.08%EURHKD-0.08%USDCNH+0.08%EURCAD-0.08%USDDKK+0.06%GBPSGD+0.05%USDCOP-0.04%EURGBP+0.04%EURCNH+0.03%AUDNOK+0.03%USDHKD+0.01%CHFSGD+0.01%EURDKK0.00%XPTUSD-5.33%UKOIL+5.05%USOIL+4.73%HG1-4.70%XAGUSD-4.69%GAGUSD-4.68%SUGAR+2.54%GAUUSD-0.96%XAUUSD-0.96%COTTON+0.72%COFFEE-0.69%XNGUSD+0.64%BTCUSD-1.69%ETHUSD-1.24%USDTUSD-0.03%XRPUSD-3.15%SOLUSD-2.10%TRXUSDT0.00%ZECUSDT-7.17%DOGEUSD-3.23%XMRUSDT-1.42%LINKUSD-1.94%XLMUSD-2.45%BCHUSDT-10.50%LTCUSD-2.25%UNIUSD-2.93%TONUSD+24.88%HBARUSDT-2.55%SUIUSD-4.12%TAOUSDT-6.03%AAVEUSD-3.38%DOTUSDT-3.52%ICPUSDT-1.55%ONDOUSDT-3.87%WLDUSDT-3.39%ARBUSDT-0.70%ATOMUSDT-5.46%JUPUSDT-4.25%INJUSDT-5.73%STXUSDT-4.53%FETUSDT-4.21%TIAUSDT-2.18%PYTHUSDT-1.56%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-2.97%WIFUSDT-5.87%OPUSDT-4.00%POLUSDT-6.02%IOTAUSDT-4.48%AXSUSDT-2.90%FARTCOINUSDT-4.36%EOSUSDT-1.67%DYDXUSDT-3.33%ORDIUSDT-1.82%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%
EP

EyePoint Pharmaceuticals, Inc. (EYPT)

NASDAQ • Healthcare

$4.34
-$0.21 (-4.8%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$4.5
Previous Close$4.34
Day Range$4.28 - $4.56
Avg. Volume (3M)7.1M
Market Cap$363.8M
52 Week Range
$3.95$19.11
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$507K100%
Gross Profitminus cost of goods$507K100%

Fundamentals & Financials

Revenue (TTM)
$2.7M
Net Income (TTM)
-$306.6M
EPS (TTM)
-$3.74
ROA (TTM)
-134.38%
Current Ratio
4.5

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-3.8%Q1 2026-$0.81
-25.3%Q2 2026-$0.99
-7.9%Q3 2026-$1.09
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -7.9%

EyePoint Pharmaceuticals trailed consensus on EPS but topped it on revenue in the second fiscal quarter of 2026, reported August 5, 2026, as revenue fell 90.5% to roughly $0.5 million from about $5.3 million a year ago. Revenue of $507,000.00 topped the $451,214.00 estimate, +12.4%, while EPS of -$1.09 trailed the -$1.01 estimate by -$0.08 (down from -$0.85 a year ago). With gross profit matching revenue at roughly $0.5 million, the quarter still posted an operating loss of about $97.4 million, and net income came in at a loss of roughly $94.5 million, improving 59.0% from a loss of about $59.4 million a year earlier. The company’s marketed ophthalmic portfolio includes ILUVIEN, YUTIQ, and DEXYCU. For the next period, consensus calls for EPS of -$0.91 on revenue of $232,154.00.

View full earnings history

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. develops and markets ophthalmic therapies for retinal and other eye disorders as a biotechnology company in healthcare. Trading on the NASDAQ Global Market as EYPT, it generates $31.4 million in FY2025 revenue from commercial eye-disease products and a pipeline aimed at chronic and sight-threatening conditions.

Name
EyePoint Pharmaceuticals, Inc.
CEO
Jay S. Duker
Website
www.eyepoint.bio
Industry
Healthcare
Year Founded
1987
Employees
214

Today's Snapshot

AI-generated

EYPT opened slightly lower at 4.32, while its sector was flat. EYPT is trading within 4.9% of its 52-week low of 3.95. EyePoint updated Phase 3 trial data for DURAVYU, its treatment for wet age-related macular degeneration.

Trading Volume

Below 10d avg (3.3M)

1.1M

vs S&P 500 Today

Strong Underperformance

-3.84%

Updated: September 10, 2026 at 15:02 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
EYPT is priced at $4.14 and shows a strong bearish setup: ADX above 34 denotes a firm downtrend, and on-balance volume is strongly negative, indicating persistent selling. The stock trades substantially below its short-, medium- and 200-day averages, which underlines the depth of the decline, while momentum readings are weak and the MACD is non-positive. Volatility is high with an ATR roughly $0.74 (≈17.9%), and although some oscillators are oversold, they have not yet offset the dominant negative signals. Technical takeaway: strong sell — trend strength, weak momentum and heavy distribution validate the bearish stance.
All signals
  • EMA (5 indicators)$4.77 - $12.38
    Sell
  • RSI (14)27.95
    Buy
  • Stochastic %K (14, 3, 3)5.65
    Buy
  • MACD Level (12, 26)-1.81
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
NRIXNurix Therapeutics, Inc.
$26.26+0.5%
KODKodiak Sciences Inc.
$33.78-3.7%
SEPNSepterna Inc
$37.97+1.6%
BCAXBicara Therapeutics Inc. Common Stock
$23.64-0.3%
SVRASavara Inc.
$5.42-2.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.